Bio-Rad Laboratories, Inc. Class A Common Stock vs Texas Instruments Incorporated — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Texas Instruments Incorporated trades at $309.8 (market cap $278.08B). The key difference: Texas Instruments Incorporated is far larger — about 34.6× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Texas Instruments Incorporated pays a 1.86% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | TXN | |
|---|---|---|
Market Cap | $8.04B | $278.08B |
Sector | Health | Technology |
52-Week High | $339.75 | $332.35 |
52-Week Low | $241.71 | $153.33 |
Enterprise Value | $7.85B | $287.03B |
Dividend Yield | — | 1.86% |
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Texas Instruments (TXN) trades at $305.55, down 1.91% with a bearish technical signal. The company shows improving fundamentals with Q1 2026 earnings beat ($1.68 vs $1.36 expected) and revenue growth to $17.68B in 2025. Recent CFO transition to Julie Knecht and strong AI-related demand from data centers provide positive catalysts. Valuation remains elevated with P/E of 51.04 and P/S of 14.78, while maintaining strong profitability with 29.11% net margin and 32.18% ROE.
TXN presents a mixed outlook with solid fundamentals offset by premium valuation. The stock offers exposure to growing AI infrastructure demand and operational improvements, but faces risks from competitive pressures and debt levels. Analyst consensus leans bullish with $317.20 price target, though technical indicators suggest near-term caution. The current price near pivot point resistance requires monitoring for breakout confirmation.
Trailing returns across standard periods
Latest headlines on both assets
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →